Abstract:The purpose of the present study was to establish a pharmacokinetic/pharmacodynamic (PK/PD) modeling approach for the dosage schedule design and decreasing the emergence of drug-resistant bacteria. The minimal inhibitory concentration (MIC) of 929 Escherichia coli isolates from broilers to enrofloxacin and ciprofloxacin was determined following CLSI guidance. The MIC50 was calculated as the populational PD parameter for enrofloxacin against E. coli in broilers. The 101 E. coli strains with MIC closest to the MIC50 (0.05 mu g/mL) were submitted for serotype identification. The 13 E. coli strains with O and K serotype were further utilized for determining pathogencity in mice. Of all the strains tested, the E. coli designated strain Anhui 112 was selected for establishing the disease model and PK/PD study. The PKs of enrofloxacin after oral administration at the dose of 10 mg/kg body weights (BW) in healthy and infected broilers was evaluated with high-performance liquid chromatography (HPLC) method. For intestinal contents after oral administration, the peak concentration (Cmax), the time when the maximum concentration reached (Tmax), and the area under the concentration-time curve (AUC) were 21.69-31.69 mu g/mL, 1.13-1.23 h, and 228.97-444.86 mu g h/mL, respectively. The MIC and minimal bactericidal concentration (MBC) of enrofloxacin against E. coli (Anhui 112) in Mueller-Hinton (MH) broth and intestinal contents were determined to be similar, 0.25 and 0.5 mu g/mL respectively. In this study, the sum of concentrations of enrofloxacin and its metabolite (ciprofloxacin) was used for the PK/PD integration and modeling. The ex vivo growth inhibition data were fitted to the sigmoid Emax (Hill) equation to provide values for intestinal contents of 24 h area under concentration-time curve/MIC ratios (AUC0-24 h/MIC) producing, bacteriostasis (624.94 h), bactericidal activity (1065.93 h) and bacterial eradication (1343.81 h). PK/PD modeling was established to simulate the efficacy of enrofloxacin for different dosage regimens. By model validation, the protection rate was 83.3%, demonstrating that the dosage regimen of 11.9 mg/kg BW every 24 h during 3 days provided great therapeutic significance. In summary, the purpose of the present study was to first design a dosage regimen for the treatment E. coli in broilers by enrofloxacin using PK/PD integrate model and confirm that this dosage regimen presents less risk for emergence of floroquinolone resistance.

Potential Pharmacokinetic Effect of Rifampicin on Enrofloxacin in Broilers: Roles of P-glycoprotein and BCRP Induction by Rifampicin

Age-Related P-Glycoprotein Expression In The Intestine And Affecting The Pharmacokinetics Of Orally Administered Enrofloxacin In Broilers

E. Coli Infection Modulates the Pharmacokinetics of Oral Enrofloxacin by Targeting P-glycoprotein in Small Intestine and CYP450 3A in Liver and Kidney of Broilers.

Lipopolysaccharide Upregulating P-Glycoprotein in Small Intestine Alters Pharmacokinetics of Orally Administered Enrofloxacin in Broilers

Use of Quercetin in Animal Feed: Effects on the P-gp Expression and Pharmacokinetics of Orally Administrated Enrofloxacin in Chicken

Pharmacokinetics, Withdrawal Time, and Dietary Risk Assessment of Enrofloxacin and Its Metabolite Ciprofloxacin, and Sulfachloropyridazine‐trimethoprim in Taihe Black‐boned Silky Fowls

Effects of Fluoroquinolones on CYP4501A and 3A in Male Broilers.

ABC Transporters and CYP3A4 Mediate Drug Interactions between Enrofloxacin and Salinomycin Leading to Increased Risk of Drug Residues and Resistance

Population Pharmacokinetics of Enrofloxacin and Its Metabolite Ciprofloxacin in Chicken Based on Retrospective Data, Incorporating First-Pass Metabolism

Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia Coli in Broilers.

Relevance Of Breast Cancer Resistance Protein To Pharmacokinetics Of Florfenicol In Chickens: A Perspective From In Vivo And In Vitro Studies

Effect of Enrofloxacin and Roxarsone on CYP450s in Pig

Abcb1 in Pigs: Molecular Cloning, Tissues Distribution, Functional Analysis, and Its Effect on Pharmacokinetics of Enrofloxacin

Effect of Enrofloxacin on the Microbiome, Metabolome, and Abundance of Antibiotic Resistance Genes in the Chicken Cecum

Intramuscular therapeutic doses of enrofloxacin affect microbial community structure but not the relative abundance of fluoroquinolones resistance genes in swine manure

Pharmacokinetics of Enrofloxacin in Meat Pigeons after a Single Intramuscular and Oral Administration

Curcumin Affects the Pharmacokinetics of Florfenicol by Downregulating the Expression of BCRP in Poultry

Studying the effect of administration route and treatment dose on the selection of enrofloxacin resistance in commensal Escherichia coli in broilers

A Proposed "Steric-Like Effect" for the Slowdown of Enrofloxacin Antibiotic Metabolism by Ciprofloxacin, and Its Mechanism.

Pharmacokinetics and Pharmacodynamics of Enrofloxacin Treatment of Escherichia Coli in a Murine Thigh Infection Modeling.

Chicken Xenobiotic Receptor Upregulates the BCRP/ABCG2 Transporter.